Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure

P. Liu, M. Zhang, M. Shoeb, D. Hogan, Luosheng Tang, Misha Syed, C. Z. Wang, Gerald Campbell, Naseem Ansari

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Because as many as half of glaucoma patients on intraocular pressure (IOP)-lowering therapy continue to experience optic nerve toxicity, it is imperative to find other effective therapies. Iron and calcium ions play key roles in oxidative stress, a hallmark of glaucoma. Therefore, we tested metal chelation by means of ethylenediaminetetraacetic acid (EDTA) combined with the permeability enhancer methylsulfonylmethane (MSM) applied topically on the eye to determine if this noninvasive treatment is neuroprotective in rat optic nerve and retinal ganglion cells exposed to oxidative stress induced by elevated IOP. Hyaluronic acid (HA) was injected into the anterior chamber of the rat eye to elevate the IOP. EDTA-MSM was applied topically to the eye for 3 months. Eyeballs and optic nerves were processed for histological assessment of cytoarchitecture. Protein-lipid aldehyde adducts and cyclooxygenase-2 (COX-2) were detected immunohistochemically. HA administration increased IOP and associated oxidative stress and inflammation. Elevated IOP was not affected by EDTA-MSM treatment. However, oxidative damage and inflammation were ameliorated as reflected by a decrease in formation of protein-lipid aldehyde adducts and COX-2 expression, respectively. Furthermore, EDTA-MSM treatment increased retinal ganglion cell survival and decreased demyelination of optic nerve compared with untreated eyes. Chelation treatment with EDTA-MSM ameliorates sequelae of IOP-induced toxicity without affecting IOP. Because most current therapies aim at reducing IOP and damage occurs even in the absence of elevated IOP, EDTA-MSM has the potential to work in conjunction with pressure-reducing therapies to alleviate damage to the optic nerve and retinal ganglion cells.

Original languageEnglish (US)
Pages (from-to)289-299
Number of pages11
JournalFree Radical Biology and Medicine
Volume69
DOIs
StatePublished - Apr 2014

Fingerprint

Oxidative stress
Chelating Agents
Intraocular Pressure
Rats
Permeability
Oxidative Stress
Metals
Edetic Acid
Optic Nerve
Optics
Retinal Ganglion Cells
Hyaluronic Acid
Cyclooxygenase 2
Therapeutics
Aldehydes
Glaucoma
Chelation
Toxicity
Inflammation
Lipids

Keywords

  • Chelation therapy
  • EDTA
  • Free radicals
  • Glaucoma
  • Glaucomatous neurodegeneration
  • Hyaluronic acid
  • Inflammation
  • Intraocular pressure
  • Metal chelation
  • Methylsulfonylmethane
  • Ocular hypertension
  • Oxidative damage
  • Oxidative stress
  • Reactive oxygen species
  • Retinal ganglion cell

ASJC Scopus subject areas

  • Biochemistry
  • Physiology (medical)

Cite this

Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure. / Liu, P.; Zhang, M.; Shoeb, M.; Hogan, D.; Tang, Luosheng; Syed, Misha; Wang, C. Z.; Campbell, Gerald; Ansari, Naseem.

In: Free Radical Biology and Medicine, Vol. 69, 04.2014, p. 289-299.

Research output: Contribution to journalArticle

@article{9816c4316bbd483cbeafa7fe54352d17,
title = "Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure",
abstract = "Because as many as half of glaucoma patients on intraocular pressure (IOP)-lowering therapy continue to experience optic nerve toxicity, it is imperative to find other effective therapies. Iron and calcium ions play key roles in oxidative stress, a hallmark of glaucoma. Therefore, we tested metal chelation by means of ethylenediaminetetraacetic acid (EDTA) combined with the permeability enhancer methylsulfonylmethane (MSM) applied topically on the eye to determine if this noninvasive treatment is neuroprotective in rat optic nerve and retinal ganglion cells exposed to oxidative stress induced by elevated IOP. Hyaluronic acid (HA) was injected into the anterior chamber of the rat eye to elevate the IOP. EDTA-MSM was applied topically to the eye for 3 months. Eyeballs and optic nerves were processed for histological assessment of cytoarchitecture. Protein-lipid aldehyde adducts and cyclooxygenase-2 (COX-2) were detected immunohistochemically. HA administration increased IOP and associated oxidative stress and inflammation. Elevated IOP was not affected by EDTA-MSM treatment. However, oxidative damage and inflammation were ameliorated as reflected by a decrease in formation of protein-lipid aldehyde adducts and COX-2 expression, respectively. Furthermore, EDTA-MSM treatment increased retinal ganglion cell survival and decreased demyelination of optic nerve compared with untreated eyes. Chelation treatment with EDTA-MSM ameliorates sequelae of IOP-induced toxicity without affecting IOP. Because most current therapies aim at reducing IOP and damage occurs even in the absence of elevated IOP, EDTA-MSM has the potential to work in conjunction with pressure-reducing therapies to alleviate damage to the optic nerve and retinal ganglion cells.",
keywords = "Chelation therapy, EDTA, Free radicals, Glaucoma, Glaucomatous neurodegeneration, Hyaluronic acid, Inflammation, Intraocular pressure, Metal chelation, Methylsulfonylmethane, Ocular hypertension, Oxidative damage, Oxidative stress, Reactive oxygen species, Retinal ganglion cell",
author = "P. Liu and M. Zhang and M. Shoeb and D. Hogan and Luosheng Tang and Misha Syed and Wang, {C. Z.} and Gerald Campbell and Naseem Ansari",
year = "2014",
month = "4",
doi = "10.1016/j.freeradbiomed.2014.01.039",
language = "English (US)",
volume = "69",
pages = "289--299",
journal = "Free Radical Biology and Medicine",
issn = "0891-5849",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure

AU - Liu, P.

AU - Zhang, M.

AU - Shoeb, M.

AU - Hogan, D.

AU - Tang, Luosheng

AU - Syed, Misha

AU - Wang, C. Z.

AU - Campbell, Gerald

AU - Ansari, Naseem

PY - 2014/4

Y1 - 2014/4

N2 - Because as many as half of glaucoma patients on intraocular pressure (IOP)-lowering therapy continue to experience optic nerve toxicity, it is imperative to find other effective therapies. Iron and calcium ions play key roles in oxidative stress, a hallmark of glaucoma. Therefore, we tested metal chelation by means of ethylenediaminetetraacetic acid (EDTA) combined with the permeability enhancer methylsulfonylmethane (MSM) applied topically on the eye to determine if this noninvasive treatment is neuroprotective in rat optic nerve and retinal ganglion cells exposed to oxidative stress induced by elevated IOP. Hyaluronic acid (HA) was injected into the anterior chamber of the rat eye to elevate the IOP. EDTA-MSM was applied topically to the eye for 3 months. Eyeballs and optic nerves were processed for histological assessment of cytoarchitecture. Protein-lipid aldehyde adducts and cyclooxygenase-2 (COX-2) were detected immunohistochemically. HA administration increased IOP and associated oxidative stress and inflammation. Elevated IOP was not affected by EDTA-MSM treatment. However, oxidative damage and inflammation were ameliorated as reflected by a decrease in formation of protein-lipid aldehyde adducts and COX-2 expression, respectively. Furthermore, EDTA-MSM treatment increased retinal ganglion cell survival and decreased demyelination of optic nerve compared with untreated eyes. Chelation treatment with EDTA-MSM ameliorates sequelae of IOP-induced toxicity without affecting IOP. Because most current therapies aim at reducing IOP and damage occurs even in the absence of elevated IOP, EDTA-MSM has the potential to work in conjunction with pressure-reducing therapies to alleviate damage to the optic nerve and retinal ganglion cells.

AB - Because as many as half of glaucoma patients on intraocular pressure (IOP)-lowering therapy continue to experience optic nerve toxicity, it is imperative to find other effective therapies. Iron and calcium ions play key roles in oxidative stress, a hallmark of glaucoma. Therefore, we tested metal chelation by means of ethylenediaminetetraacetic acid (EDTA) combined with the permeability enhancer methylsulfonylmethane (MSM) applied topically on the eye to determine if this noninvasive treatment is neuroprotective in rat optic nerve and retinal ganglion cells exposed to oxidative stress induced by elevated IOP. Hyaluronic acid (HA) was injected into the anterior chamber of the rat eye to elevate the IOP. EDTA-MSM was applied topically to the eye for 3 months. Eyeballs and optic nerves were processed for histological assessment of cytoarchitecture. Protein-lipid aldehyde adducts and cyclooxygenase-2 (COX-2) were detected immunohistochemically. HA administration increased IOP and associated oxidative stress and inflammation. Elevated IOP was not affected by EDTA-MSM treatment. However, oxidative damage and inflammation were ameliorated as reflected by a decrease in formation of protein-lipid aldehyde adducts and COX-2 expression, respectively. Furthermore, EDTA-MSM treatment increased retinal ganglion cell survival and decreased demyelination of optic nerve compared with untreated eyes. Chelation treatment with EDTA-MSM ameliorates sequelae of IOP-induced toxicity without affecting IOP. Because most current therapies aim at reducing IOP and damage occurs even in the absence of elevated IOP, EDTA-MSM has the potential to work in conjunction with pressure-reducing therapies to alleviate damage to the optic nerve and retinal ganglion cells.

KW - Chelation therapy

KW - EDTA

KW - Free radicals

KW - Glaucoma

KW - Glaucomatous neurodegeneration

KW - Hyaluronic acid

KW - Inflammation

KW - Intraocular pressure

KW - Metal chelation

KW - Methylsulfonylmethane

KW - Ocular hypertension

KW - Oxidative damage

KW - Oxidative stress

KW - Reactive oxygen species

KW - Retinal ganglion cell

UR - http://www.scopus.com/inward/record.url?scp=84896698567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896698567&partnerID=8YFLogxK

U2 - 10.1016/j.freeradbiomed.2014.01.039

DO - 10.1016/j.freeradbiomed.2014.01.039

M3 - Article

C2 - 24509160

AN - SCOPUS:84896698567

VL - 69

SP - 289

EP - 299

JO - Free Radical Biology and Medicine

JF - Free Radical Biology and Medicine

SN - 0891-5849

ER -